Serious adverse occasions are summarized in Table S3 in the Supplementary Appendix. Adverse events of grade 3 or higher that occurred more often in the ibrutinib group than in the ofatumumab group included diarrhea and atrial fibrillation ; the latter event needed cessation of therapy in a single patient. An additional four patients in the ibrutinib group and one patient in the ofatumumab group acquired grade one or two 2 atrial fibrillation. Bleeding-related adverse events of any grade were more common in the ibrutinib group than in the ofatumumab group . Main hemorrhage was reported in two individuals in the ibrutinib group and three patients in the ofatumumab group.and Actelion Pharmaceuticals Ltd. (SWX: ATLN. Actelion will be primarily in charge of the applicable regulatory and commercialization actions for XIAFLEX in these national countries. XIAFLEX has been accepted by the U.S. Food and Medication Administration and the European Medicines Agency as cure for Dupuytren’s contracture, and is in development in Japan also. In addition, XIAFLEX has been accepted for review by Wellness Canada for the treating Dupuytren’s contracture in Canada and regulatory action is expected in the second fifty % of 2012. Today, Auxilium and Actelion possess forged a partnership, which we believe has the opportunity to give, at the mercy of regulatory approval, the 1st, effective nonsurgical treatment for just two illnesses in multiple brand-new geographies, said Adrian Adams, CEO and President of Auxilium.